1-3 of 3
Masahiro Oura, MD
Close
Sort by
Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3111.
https://doi.org/10.1182/blood-2019-127679
Published: 2019
Journal Articles

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Shuji Ozaki, MD PhD, Takeshi Harada, MD PhD, Kengo Udaka, MD, Etsuko Sekimoto, MD PhD, Hironobu Shibata, MD PhD, Toshio Shigekiyo, MD PhD, Hikaru Yagi, MD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Masahiro Oura, MD, Shiro Fujii, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Masahiro Abe, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5577.
https://doi.org/10.1182/blood-2018-99-115818
Published: 2018
Journal Articles

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Takeshi Harada, MD PhD, Asuka Oda, PhD, Yohann Grondin, PhD, Jumpei Teramachi, DDS, PhD, Ariunzaya Bat-Erdene, MD PhD, Masami Iwasa, MD, Masahiro Oura, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Shiro Fujii, MD, Hirokazu Miki, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1939.
https://doi.org/10.1182/blood-2018-99-114086
Published: 2018